2023年5月1日 · On March 23, 2022, the FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, also known as 177Lu-PSMA-617) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen r …

2022年10月20日 · The novel radiopharmaceutical [177 Lu]Lu-PSMA-617 causes challenges, but also great opportunities for our healthcare systems, particularly for nuclear medicine and urology. PSMA-617 shows high efficacy and low side effects and represents an important next step towards novel theranostics.

2024年11月15日 · 该试验旨在评估177Lu-PSMA-617联合标准治疗（SOC）在既往接受过至少1种雄激素受体抑制剂和1-2种紫杉类方案治疗且PSMA表达阳性的mCRPC患者中的疗效。 研究结果显示，与SOC组相比，177Lu-PSMA-617联合SOC组显著改善mCRPC患者的无进展生存期（PFS）和总生存期（OS）。 在mPFS方面，177Lu-PSMA-617组有效延长患者的mFPS（8.7个月 vs 3.4个月），疾病进展或者死亡风险降低60% （HR 0.40，99.2% CI：0.29~0.57）。 …

Lutetium Lu 177 (177Lu), the radioactive (tracer) component being delivered by prostate-specific membrane antigen (PSMA)-617, has physical properties that make it ideal radionuclide (imaging tests that uses a small dose tracer) for treatment of metastatic castrate-resistant prostate cancer (mCRPC). 177Lu-PSMA-617 works by binding to prostate ...

Background: Enzalutamide and lutetium-177 [177 Lu]Lu-prostate-specific membrane antigen (PSMA)-617 both improve overall survival in patients with metastatic castration-resistant prostate cancer. Androgen and PSMA receptors have a close intracellular relationship, with data suggesting complementary benefit if targeted concurrently.

Background: 177 Lu-PSMA-617 (Lu-PSMA) is an emerging therapy in men with metastatic castration-resistant prostate cancer. Paired theranostic agents have the potential to visually identify phenotypes that will respond to targeted therapy.

Lutetium Lu 177 (177Lu), the radioactive (tracer) component being delivered by prostate-specific membrane antigen (PSMA)-617, has physical properties that make it ideal radionuclide (imaging tests that uses a small dose tracer) for treatment of metastatic castrate-resistant prostate cancer (mCRPC). 177Lu-PSMA-617 works by binding to prostate ...

2024年5月29日 · Real world outcomes with cabazitaxel (cab) plus carboplatin (car) in metastatic castration-resistant prostate cancer (mCRPC). Background: 177 Lu-PSMA-617 was recently approved for the treatment of patients with mCRPC in the USA.

2023年11月30日 · Lutetium-177 [177 Lu]Lu-PSMA-617, also known as prostate-specific membrane antigen (PSMA) radioligand therapy, is a small molecule with a radioactive payload enabling targeted treatment of prostate cancer. 1 In the first analysis of the TheraP trial, 2 we reported that in patients with progressive metastatic castration-resistant prostate cancer ...

2022年8月8日 · In 2014, ASCO published a guideline on systemic therapy in men with metastatic castration-resistant prostate cancer (mCRPC).1 In March 2022, the US Food and Drug Administration (FDA) approved 177Lu-tetium-PSMA-617 (177Lu-PSMA-617), a radioligand therapy that delivers targeted beta-particle radiation to …